The increased market awareness for drugs targeting rare and life-threatening diseases has
coincided with a rise in the number of patients requesting early access to these medicines.
To meet the demand, an increasing number of pharmaceutical and biotechnology
companies are deciding to develop early access programmes. However, navigating the
nuances and complexities of these programmes has proven to be a resource draining task
and companies are looking to develop standards and streamline their processes.
It is imperative for companies to have a comprehensive planning strategy before the
implementation of these programmes that needs to take a number of factors into
consideration.
Pharmaceutical specialists, Dr. Carlos R. Camozzi and Ramana Sonty spoke to Pharma IQ in regards to the top 6 factors to consider in an early access programme planning strategy.
|
|
Have Your Say Rate this feature and give us your feedback in the comments section below |
|